Notice of allowance in European patent application

We are pleased to announce that we have received a notice of allowance (Communication under Rule 71(3) EPC) in our European patent application relating to novel sortilin inhibitors. Sortina’s sortilin inhibitors hold promise in treatment of, among others, cancer and neurodegenerative diseases. This milestone represents a significant advancement in our efforts to protect and further develop innovative therapeutic solutions. The European patent will be instrumental in supporting continued progress across all our projects, with cancer as main focus. We are excited about the opportunities this approval opens up for us in Europe as we move closer to delivering life-saving therapies to patients in need.

Sortina Pharma AB announces official publication of the issued Swedish patent no. 2151469-0.

Sortina Pharma AB announces the appointment of new members to its Board of Directors, strengthening the company for acceleration and positioning in the development of world leading anti-Sortilin small molecule therapeutics.

Sara Rhost presenting Sortina Pharma on Lifesciencedagen. See the presentation (held in swedish).

Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research into product development. She has extensive experience in…

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.

With the agreement that has now been concluded between Iscaffpharma and Sortina Pharma, more effective products to cure aggressive breast cancer can be generated. Sortina Pharma, which is developing…

Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion.